Form 4: Disc Medicine COO Yu Yen-Wen Jonathan Acquires Shares and Options

Chief Operating Officer of Disc Medicine, Yu Yen-Wen Jonathan, reports acquisition of shares and options in the company.

Summary

• Yu Yen-Wen Jonathan, the Chief Operating Officer of Disc Medicine, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On February 10, 2025, Yu acquired 24,000 shares of common stock in the form of restricted stock units (RSUs) and an option to purchase 36,000 shares.
• The RSUs vest in four annual installments starting February 15, 2026, contingent upon continued service.
• The stock options vest monthly over 48 months beginning March 10, 2025, also contingent upon continued service.
• Following the reported transactions, Yu directly owns 42,165 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the COO's increased stake in the company, suggesting confidence in its future performance. However, it's a routine filing and doesn't contain groundbreaking news.

Positives

• The acquisition of shares and options by the COO signals confidence in the company's future prospects.
• The vesting schedules for both the RSUs and stock options incentivize continued service and commitment from the COO.

Risks

• The value of the acquired shares and options is subject to the market performance of Disc Medicine's stock.
• The vesting of the RSUs and stock options is contingent upon the COO's continued service, creating a potential risk if the COO were to leave the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the acquisition of equity suggests an expectation of future value appreciation.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the COO's investment in the company's future.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to align management's interests with those of shareholders.
• Vesting schedules are standard for both stock options and restricted stock units, typically ranging from 3 to 5 years.
• The specific terms of the equity grants (e.g., vesting schedule, exercise price) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the COO's increased ownership as a positive signal.
• Employees may be motivated by the alignment of management's interests with the company's success.

Key Dates

Keywords

Disc Medicine, Yu Yen-Wen Jonathan, Chief Operating Officer, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Vesting